Document:

Document

EXHIBIT 10.2

HC2 Holdings, Inc.
450 Park Avenue, 30th Floor
New York, New York 10022

Lancer Capital LLC
777 South Flagler Drive, Suite 800, West Tower
West Palm Beach, Florida 33401
Attention: Avram Glazer
Email:      a.g@mac.com
July 5, 2020
Ladies and Gentlemen:
Reference is hereby made to that certain Agreement, dated as of May 13, 2020 (as amended, supplemented or otherwise modified from time to time in accordance with its terms, the “Agreement”), by and between Lancer Capital LLC, a Delaware limited liability company (“Lancer Capital”), and HC2 Holdings, Inc., a Delaware corporation (the “Company”). Capitalized terms used but not otherwise defined herein shall have the respective meanings ascribed to such terms in the Agreement.
In connection with the Company’s announcement on June 11, 2020 that, effective as of such date, Philip A. Falcone is no longer serving as the Chief Executive Officer of the Company, the board of directors of the Company (the “Board”) has determined not to include Mr. Falcone in the Company’s slate of directors for its 2020 annual meeting of stockholders (the “2020 Annual Meeting”), scheduled to be held on July 8, 2020. In connection with the Agreement and that certain cooperation agreement, dated as of May 13, 2020, by and among MG Capital Management Ltd., Percy Rockdale LLC, Rio Royal LLC and the Company (the “MG Capital Agreement”), and the transactions contemplated thereby, and notwithstanding anything to the contrary contained in the Agreement and the MG Capital Agreement, each of the Parties acknowledges, as a result of the foregoing and certain other matters, that (i) Mr. Falcone will not be included on the 2020 Director Slate, (ii) the Board will take such actions as are necessary to reduce the size of the Board to six (6) directors, effective as of the completion of the 2020 Annual Meeting on July 30, 2020, and (iii) the 2020 Annual Meeting will be convened on July 8, 2020, solely for purposes of adjourning the 2020 Annual Meeting to July 30, 2020.
The parties hereby acknowledge and agree that nothing in this letter shall constitute a violation of the other terms and conditions of the Agreement.
Except as otherwise expressly provided herein, all of the terms, agreements and conditions of the Agreement remain unwaived and unchanged and continue in full force and effect. This letter is limited precisely as written and shall not be deemed to be a waiver of any other term, agreement or condition of the Agreement. The provisions of Sections 8 through 10 and 12 through 17 of the Agreement are hereby incorporated herein by reference, mutatis 

mutandis, as if set forth herein and shall apply to this letter. Any conflict arising between this letter and the Agreement shall be resolved in favor of the terms and intent of this letter.
[Signature Pages Follow]

2

Very truly yours,
HC2 HOLDINGS, INC.

By: /s/ Joseph A. Ferraro   
        Name: Joseph A. Ferraro
        Title:  Chief Legal Officer

cc:   Richard J. Grossman (by email)
          Skadden, Arps, Slate, Meagher & Flom LLP

         Christopher R. Rodi (by email)
          Woods Oviatt Gilman LLP

[Signature Page to Lancer Capital Letter Agreement]

Agreed and accepted as of the date first written above:

Lancer Capital LLC
By: /s/ Avram A. Glazer___________
Name:  Avram A. Glazer
Title:  Sole Member

[Signature Page to Lancer Capital Letter Agreement]Document

EXHIBIT 10.3

HC2 Holdings, Inc.
450 Park Avenue, 30th Floor
New York, New York 10022

JDS1, LLC
2200 Fletcher Avenue, Suite 501
Fort Lee, New Jersey 07024
Attention:  Julian Singer
Telephone: +1-201-592-3400
(By Email)

CCUR Holdings, Inc.
6470 East Johns Crossing, Suite 490
Duluth, Georgia 30097
Attention:  Warren Sutherland
(By Email)
July 5, 2020
Ladies and Gentlemen:
Reference is hereby made to that certain Agreement, dated as of May 13, 2020 (as amended, supplemented or otherwise modified from time to time in accordance with its terms, the “Agreement”), by and among JDS1, LLC, a Delaware limited liability company, CCUR Holdings, Inc., a Delaware corporation (collectively, “JDS1”), and HC2 Holdings, Inc., a Delaware corporation (the “Company”). Capitalized terms used but not otherwise defined herein shall have the respective meanings ascribed to such terms in the Agreement.
In connection with the Company’s announcement on June 11, 2020 that, effective as of such date, Philip A. Falcone is no longer serving as the Chief Executive Officer of the Company, the board of directors of the Company (the “Board”) has determined not to include Mr. Falcone in the Company’s slate of directors for its 2020 annual meeting of stockholders (the “2020 Annual Meeting”), scheduled to be held on July 8, 2020. In connection with the Agreement and that certain cooperation agreement, dated as of May 13, 2020, by and among MG Capital Management Ltd., Percy Rockdale LLC, Rio Royal LLC and the Company (the “MG Capital Agreement”), and the transactions contemplated thereby, and notwithstanding anything to the contrary contained in the Agreement and the MG Capital Agreement, each of the Parties acknowledges, as a result of the foregoing and certain other matters, that (i) Mr. Falcone will not be included on the 2020 Director Slate, (ii) the Board will take such actions as are necessary to reduce the size of the Board to six (6) directors, effective as of the completion of the 2020 Annual Meeting on July 30, 2020, and (iii) the 2020 Annual Meeting will be convened on July 8, 2020, solely for purposes of adjourning the 2020 Annual Meeting to July 30, 2020.

The parties hereby acknowledge and agree that nothing in this letter shall constitute a violation of the other terms and conditions of the Agreement.
Except as otherwise expressly provided herein, all of the terms, agreements and conditions of the Agreement remain unwaived and unchanged and continue in full force and effect. This letter is limited precisely as written and shall not be deemed to be a waiver of any other term, agreement or condition of the Agreement. The provisions of Sections 8 through 10 and 12 through 17 of the Agreement are hereby incorporated herein by reference, mutatis mutandis, as if set forth herein and shall apply to this letter. Any conflict arising between this letter and the Agreement shall be resolved in favor of the terms and intent of this letter.
[Signature Pages Follow]

2

Very truly yours,
HC2 HOLDINGS, INC.

By: /s/ Joseph A. Ferraro   
        Name: Joseph A. Ferraro
        Title:  Chief Legal Officer

cc:   Richard J. Grossman (by email)
          Skadden, Arps, Slate, Meagher & Flom LLP

         Paul N. Silverstein (by email)
         Melinda Brunger
          Hunton Andrews Kurth LLP

[Signature Page to JDS1 Letter Agreement]

Agreed and accepted as of the date first written above:

JDS1, LLC
By: /s/ Julian Singer ___________
Name:  Julian Singer
Title:  President

CCUR Holdings, Inc.
By: /s/ Warren Sutherland ______
Name:  Warren Sutherland 
Title: Chief Financial Officer

[Signature Page to JDS1 Letter Agreement]EX-10.21

 Exhibit 10.21 

CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD
LIKELY CAUSE COMPETITIVE HARM IF PUBLICLY DISCLOSED. 
  

			
	CONFIDENTIAL	  	EXECUTION VERSION

 AMENDMENT NO. 3 TO THE COLLABORATION AND LICENSE AGREEMENT 

THIS AMENDMENT NO. 3 TO THE COLLABORATION AND LICENSE AGREEMENT (“Amendment”) is made and entered into, effective as of April 1,
2020 (“Amendment No. 3 Effective Date”), by and between Vir Biotechnology, Inc., a Delaware corporation with offices at with an office at 499 Illinois Street, San Francisco, California 94158
(“Vir”), and Alnylam Pharmaceuticals, Inc., a Delaware corporation located at 675 West Kendall Street – Henri A. Termeer Square, Cambridge, Massachusetts 02142 (“Alnylam”). Each of Vir and Alnylam are
referred to in this Amendment as a “Party” and together, the “Parties”. 
 BACKGROUND 

WHEREAS, the Parties have entered into that certain Collaboration and License Agreement effective as of October 16, 2017 (as amended by Letter Agreement
dated November 13, 2018 and by Amendment No. 1 to the Collaboration and License Agreement effective December 17, 2019 and Amendment No. 2 to the Collaboration and License Agreement effective March 3, 2020, the
“Collaboration Agreement”) pursuant to which the Parties entered into a collaboration to develop and commercialize certain compounds and products based on Alnylam’s RNAi technology, in connection with Hepatitis B and other
infectious diseases; 
 WHEREAS, pursuant to Section 3.1(b) and 3.1(c) of the Collaboration Agreement Vir has selected five (5) ID Collaboration
Targets; 
 WHEREAS, the Parties desire to add three additional ID Collaboration Targets to the Collaboration, bringing the total number of ID Collaboration
Targets to eight (8) on the terms and conditions described in this Amendment; and 
 WHEREAS, Section 14.4 of the Collaboration Agreement provides
that the Collaboration Agreement may only be modified by a written instrument duly executed by an authorized representative of each Party. 
 NOW,
THEREFORE, the Parties desire, for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, to amend the Collaboration Agreement as set forth in this Amendment. 

ARTICLE 1 
 DEFINITIONS

 1.1 Capitalized Terms. Capitalized terms used in this Amendment shall have the meanings set forth in the Collaboration Agreement unless
otherwise defined and set forth in this Amendment. Except as expressly modified by this Amendment, the remainder of the Collaboration Agreement shall remain in force in accordance with its terms and without any modification. 

ARTICLE 2 
 AMENDMENTS

 2.1 Addition of New Section 1.1.54B: Article 1 of the Collaboration Agreement is hereby amended by adding a new
Section 1.1.54B immediately after Section 1.1.54A as follows: 
 1.1.54B “Coronaviruses” shall
mean any coronavirus, or isolate or isoform thereof, that causes severe acute respiratory syndrome in humans, including SARS-CoV-2, SARS-CoV and MERS-CoV. 

  
 1 

 2.2 Amendment to Section 1.1.77: Section 1.1.77 of the Collaboration
Agreement is hereby amended in its entirety as follows: 
 1.1.77 “Field” shall mean (a) for all
Collaboration Targets other than the Host Factor Targets, all uses and purposes, including the treatment, palliation, diagnosis or prevention of any human disease, disorder or condition, and (b) for the Host Factor Targets, the treatment,
palliation, diagnosis or prevention of Coronaviruses, but in each case ((a)-(b)) excluding applications in agriculture, horticulture, forestry, aquaculture, and/or residential markets relating to plants, fish, arthropods and/or pests and pathogens
thereof (e.g., home, lawn and/or garden). 
 2.3 Addition of New Section 1.1.90A: Article 1 of the Collaboration Agreement
is hereby amended by adding a new Section 1.1.90A immediately after Section 1.1.90 as follows: 
 1.1.90A
“Host Factor” shall mean a human trait that affects susceptibility to disease. 
 2.4 Addition of New
Section 1.1.90B: Article 1 of the Collaboration Agreement is hereby amended by adding a new Section 1.1.90B immediately after Section 1.1.90A as follows: 

90B “Host Factor Targets” shall mean (a) the two Initial Host Factor Targets, (b) an additional Host
Factor selected by the Parties in accordance with Section 3.1(d)(i), and (iii) a replacement Host Factor selected by the Parties in accordance with Section 3.1(d)(i). 

2.5 Amendment to Section 1.1.92: Section 1.1.92 of the Collaboration Agreement is hereby amended in its entirety as
follows: 
 1.1.92 “ID Collaboration Target” shall mean an ID Target that is designated for an ID Program
pursuant to Section 3.1(b), 3.1(c) or 3.1(d). 
 2.6 Amendment to Section 1.1.97: Section 1.1.97 of the
Collaboration Agreement is hereby amended in its entirety as follows: 
 1.1.97 “ID Target” shall mean
(a) for all Targets other than the Host Factor Targets, a Target primarily for intervention in the treatment, palliation, diagnosis or prevention of Infectious Disease in humans or animals, and (b) for the Host Factor Targets, a Target for
intervention in the treatment, palliation, diagnosis or prevention of Coronaviruses in humans or animals. 
 2.7 Addition of
Section 1.1.99A: Article 1 of the Collaboration Agreement is hereby amended by adding a new Section 1.1.99A immediately after Section 1.1.99 as follows: 

1.1.99A “Initial Host Factor Targets” shall mean (a) angiotensin converting enzyme 2 (ACE2) and
(b) transmembrane serine protease 2 (TMPRSS2). 
 2.8 Amendment to Section 1.1.182: Section 1.1.182 of the
Collaboration Agreement is hereby amended in its entirety as follows: 
 1.1.182 “Vir Improvements”
means any patented improvement, discovery or Know-How that (a) is first conceived or reduced to practice, or with respect to inventions and discoveries other than patentable inventions, otherwise
identified, discovered, made or developed, solely by individuals who are employees, agents or consultants of Vir or its Affiliates in the course of conducting Development, Manufacturing or Commercialization activities with respect to Licensed
Products under this Agreement, (b) is Controlled by Vir or its Affiliates, and (c) constitutes an improvement that would otherwise be dominated by Alnylam Core Technology Patent Rights, including, as applicable, formulation technology. Vir
Improvements excludes [***]. 

  
 2 

 2.9 Amendment of Section 3.1: Section 3.1(d) of the Collaboration
Agreement is hereby amended to add the following Section 3.1(d): 
 (a) Host Factor Targets. 

(i) Host Factor Targets. Notwithstanding the provisions of Section 3.1(b) or 3.1(c) above, the Parties agree to
collaborate in a program to Develop RNAi Products Directed to the Host Factor Targets for use in the Field, which program may include the use of [***], until Development Candidate selection pursuant to Section 3.3 below. The program shall be
directed to the Initial Host Factor Targets, and the Parties may mutually agree to the selection of up to one (1) additional Host Factor as an ID Collaboration Target. Once mutually agreed by the Parties, the new Host Factor Target shall be
added to the list of ID Collaboration Targets listed on Schedule D. The Host Factor Targets shall be ID Collaboration Targets and shall be in addition to, and not in lieu of, the five (5) ID Collaboration Targets described in Sections
3.1(b) and 3.1(c). Notwithstanding any provision of Section 3.3(b) to the contrary, if Alnylam has not commenced work pursuant to a DC Workplan for a given Host Factor Target, Vir shall have the right to propose to replace such Host Factor
Target with a replacement Host Factor pursuant to this Section 3.1(d), provided that such proposed replacement Host Factor is discussed and mutually agreed upon by the Parties (which discussions may occur via the JSC). If the Parties mutually
agree to designate the proposed replacement Host Factor as a Host Factor Target, then Schedule D shall be updated to include such new Host Factor Target as an ID Collaboration Target, and the Parties shall develop an ID Development Plan for such new
ID Collaboration Target in accordance with Section 3.2(a). The Host Factor Target that is replaced shall be classified as an “Abandoned ID Target” and shall cease to be an ID Collaboration Target under this Agreement, Vir’s
Program Option and other rights with respect to such Abandoned ID Target and any RNAi Products Directed to such Abandoned ID Target shall terminate and the provisions of Section 4.1(b) shall apply to the Abandoned ID Target and the ID Program
for such Abandoned IT Target. Unless otherwise mutually agreed by the Parties, the Parties shall not replace more than one (1) Host Factor Target and, for clarity, at no time during the Term shall there be more than three (3) Host Factor
Targets. 
 (ii) ID Development Plan. The initial ID Development Plan for the Host Factor Targets developed by the JSC
pursuant to Section 3.2(a) shall include the following responsibilities of the Parties and unless otherwise agreed by the Parties, Alnylam’s DC Workplan for the Host Factor Targets shall be limited to the following responsibilities of
Alnylam: 
  

			
	 Host Factor Target ID Development Plan
Activities
Prior to Development Candidate Selection
	  	 Responsible
Party(ies)

	 [***]
	  	[***]
	 [***]
	  	[***]
	 [***]
	  	[***]
	 [***]
	  	[***]
	 [***]
	  	[***]
	 [***]
	  	[***]
	 [***]
	  	[***]
	 [***]
	  	[***]

 2.10 Amendment of Section 3.4(b). Section 3.4(b) of the Collaboration Agreement is
hereby amended in its entirety as follows: 
 (b) ID Programs. Subject to the exercise by Alnylam of its
Profit-Sharing Option pursuant to Section 4.2, with respect to an ID Licensed Product, Vir shall bear 100% of the Program Costs incurred by the Parties during the Collaboration Term for each ID Program in conducting each ID Program pursuant to
the Development Plan for such ID Program, including ID Licensed Product supplied by Alnylam pursuant to Section 5.1(a)(ii); provided, however, that Alnylam shall bear the Program Costs incurred by Alnylam [***]

  
 3 

 
under the DC Workplan for the COV Target ID Program and the Host Factor Target ID Programs. In addition, (i) [***], and (ii) the Parties shall each bear fifty percent (50%) of all Program
Costs in connection with the Manufacture of non-GMP Drug Product required for nonclinical use prior to filing of an IND for the first Licensed Product in each of the COV Target ID Program and the Host Factor
Target ID Programs. In no event shall any of the Host Factor Target ID Programs be conducted outside of the Field. 
 2.11 Amendment of
Section 3.5(c). Section 3.5(c) of the Collaboration Agreement is hereby amended in its entirety as follows: 

(c) ID Programs. After exercise of its Program Option with respect to an ID Program, Vir shall use Commercially
Reasonable Efforts to Develop, obtain Regulatory Approval and following Regulatory Approval Commercialize [***] ID Licensed Product Directed to the ID Collaboration Target in such ID Program in the Field in [***] Major Markets, provided that solely
with respect to the COV Target ID Program and the Host Factor Target Programs, [***], Vir may [***]; provided, however, that [***] with respect to the COV Target ID Program or such Host Factor Target ID Program (as applicable). 

2.12 Amendment of Section 4.1(a). Section 4.1(a) of the Collaboration Agreement is hereby amended in its entirety, as
follows: 
 (a) With respect to each ID Program, Alnylam hereby grants Vir an exclusive option (“Program
Option”) to obtain a Program License for such ID Program. Vir may exercise its Program Option with respect to an ID Program by written notice to Alnylam (“Program Option Notice”) at any time prior to the date that is [***]
after the earlier of (i) [***] and (ii) the date that is [***] after [***] (“Program Option Period”). Upon Vir’s giving a Program Option Notice to Alnylam, Vir shall pay Alnylam (x) the Program Option Exercise Fee,
which is payable within [***] after Vir’s exercise of such Program Option for such ID Program, and (y) any outstanding undisputed Program Costs due to Alnylam for such ID Program, within [***] after receipt by Vir of any invoice therefor.
Upon payment in full of the Program Option Exercise Fee and any outstanding undisputed Program Costs as set forth above, (i) Alnylam shall and hereby does grant to Vir the Program License with respect to such ID Program as set forth in
Section 6.1(b)(ii), and (ii) subject to the exercise by Alnylam of its Profit-Sharing Option pursuant to Section 4.2 with respect to an ID Licensed Product and Alnylam’s responsibilities for ID Licensed Product Manufacturing
[***] pursuant to Section 5.1(a), [***], for the further Development, Manufacture and Commercialization of the ID Licensed Products in such ID Program. Notwithstanding anything herein to the contrary, no Program Option Exercise Fee shall be
payable with respect to the COV Target ID Program or the Host Factor Target ID Programs, and the licenses granted to Vir in Sections 6.1(b)(i) and (ii) shall become effective for the COV Target ID Program and a given Host Factor Target ID
Program automatically upon Vir’s delivery to Alnylam of a Program Option Notice for such COV Target ID Program or such Host Factor Target ID Program (as applicable) and payment of all undisputed Program Costs reimbursable to Alnylam for such
COV Target ID Program or such Host Factor Target ID Program (as applicable). 
 2.13 Amendment of Section 6.1(d).
Section 6.1(d) of the Collaboration Agreement is hereby amended in its entirety, as follows: 
 (d) Retained
Rights. Notwithstanding the license grants in Sections 6.1(a) and 6.1(b), Alnylam retains the rights under Alnylam Intellectual Property (a) to Develop and Manufacture Licensed Products in the Field in the Territory solely for the purpose
and only to the extent necessary for the performance of its obligations under this Agreements, and (b) subject to Alnylam’s obligations under Section 10.5(a), for [***]. Notwithstanding anything herein to the contrary, (i) with
respect to the COV Target and each Host Factor Target, neither Vir nor its Affiliates, directly or indirectly (alone or with an affiliate or Third Party), shall have any right or license under this Agreement to any Licensed Product for the COV
Target or such Host Factor Target to [***]. 

  
 4 

 2.14 Amendment of Section 7.3(a)(ii). Section 7.3(a)(ii) of the
Collaboration Agreement is hereby amended in its entirety as follows: 
 (ii) ID Licensed Products other than ID Licensed
Products Directed to the COV Target or the Host Factor Targets, with respect to which Vir has exercised its Program Option: 
  

			
	 Milestone Event
	  	 Milestone Payment

	 [***]
	  	[***]
	 [***]
	  	[***]
	 [***]
	  	[***]
	 [***]
	  	[***]
	 [***]
	  	[***]

 2.15 Amendment of Section 7.3(a). Section 7.3(a) of the Collaboration Agreement is
hereby amended to add the following Section 7.3(a)(iv) to the end of such Section: 
 (iv) ID Licensed Products Directed
to each Host Factor Target with respect to which Vir has exercised its Program Option: 
  

			
	 Milestone Event
	  	 Milestone Payment

	 [***]
	  	[***]
	 [***]
	  	[***]

 2.16 Amendment of Section 7.5(b). Section 7.5(b) of the Collaboration Agreement is
hereby amended by inserting the following at the end of such Section: 
 ; provided, however, that solely with respect to an ID
Licensed Product Directed to the COV Target or a Host Factor Target, if (i) Vir or its Related Parties sell such ID Licensed Product to a Biodefense Authority in a country, (ii) such sale is for the purposes of [***], and (iii) the
aggregate amount of such Net Sales of such ID Licensed Product to such Biodefense Authority during such Calendar Year is [***] of such ID Licensed Product on which such Net Sales are based, then (1) Vir shall pay Alnylam a [***] royalty on such
Net Sales [***] by Alnylam or its Affiliates to Third Parties under any applicable Alnylam In-License with respect to such ID Licensed Product sales, (2) such royalty shall [***], and (3) such Net
Sales shall not be [***] Net Sales of such ID Licensed Product. 
 2.17 Amendment of Section 10.5(d). Section 10.5(d)
of the Collaboration Agreement is hereby amended in its entirety as follows: 
 (d) [***]. 

2.18 Amendment of Section 10.5. Section 10.5 of the Collaboration Agreement is hereby amended to add the following
Section 10.5(e) to the end of such Section: 
 (e) for each Host Factor Target, neither Vir nor its Affiliates shall:
(i) alone or with or for any Third Party, research, develop, manufacture or commercialize any Licensed Product Directed to such Host Factor Target outside of the Field; (ii) grant a license, sublicense or other rights to any Third Party to
conduct any of the activities in the foregoing clause (i) with respect to any Licensed Product Directed to such Host Factor Target outside of the Field; or (iii) transfer, assign, convey or otherwise sell any Licensed Product Directed to
such Host Factor Target outside of the Field. 
 2.19 Amendment of Schedule A (Existing Alnylam Third Party Agreements). Schedule A (Existing
Alnylam Third Party Agreements) of the Collaboration Agreement is hereby amended as follows. [***]: 
 [***] 

  
 5 

 2.20 Amendment of Schedule D (ID Targets, Reserved Targets and ID Collaboration Targets).
Schedule D (ID Targets, Reserved Targets and ID Collaboration Targets) of the Collaboration Agreement is hereby amended by adding the [***]. 

ARTICLE 3 
 MISCELLANEOUS

 3.1 No Waiver. Nothing in this Amendment is intended to operate as a waiver of any claims either Party may have against the other Party
arising prior to the date of this Amendment, including any claims arising prior to the date of this Amendment with respect to the performance of the Parties under the Collaboration Agreement. Any delay in enforcing a party’s rights under this
Amendment or the Collaboration Agreement, or any waiver as to a particular default or other matter, will not constitute a waiver of such party’s rights to the future enforcement of its rights under this Amendment or the Collaboration Agreement,
except with respect to an express written waiver relating to a particular matter for a particular period of time signed by an authorized representative of the waiving Party, as applicable. 

3.2 Miscellaneous. This Amendment shall be governed by and interpreted in accordance with the law of the State of New York, U.S.A., without
reference to any principles of conflicts of laws to the contrary. The United Nations Convention on Contracts for the International Sale of Goods shall not apply to the transactions contemplated by this Amendment. Except as specifically amended by
this Amendment, the terms and conditions of the Collaboration Agreement shall remain in full force and effect. This Amendment may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together shall
constitute one and the same instrument. Signatures transmitted by PDF shall be treated as original signatures. Except to the extent expressly provided herein, the Collaboration Agreement, as amended by this Amendment, together with the Commitment
Letter between the Parties entered into on the Commitment Letter Date and the Stock Purchase Agreement, including all appendices, exhibits and schedules to each of the foregoing, constitute the entire agreement between the Parties relating to the
subject matter of the Collaboration Agreement and supersedes all previous oral and written communications, including all previous agreements, between the Parties. 

  
 6 

 IN WITNESS WHEREOF, on the Amendment No. 3 Effective Date Vir and Alnylam have caused this Amendment to
be duly executed by their authorized representatives. 
  

			
	 Vir Biotechnology, Inc.

		
	 Name:
	 	 /s/ George Scangos

	 Title:
	 	 George Scangos

	 Date:
	 	 Chief Executive Officer

  

			
	 Alnylam Pharmaceuticals, Inc.

		
	 Name:
	 	 /s/ Yvonne Greenstreet

	 Title:
	 	 Yvonne Greenstreet

	 Date:
	 	 Chief Operating Officer

  
 7

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00311-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00311-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00311-of-00352.parquet"}]]